LOXL2 and pancreatic ductal adenocarcinoma: However, in pancreatic ductal adenocarcinoma, the ECM is also a protective factor, as demonstrated by impairing ECM with an anti-lysyloxidase-like 2 (LOXL2) antibody in vivo, hence accelerating tumor progression and decreasing overall survival (OS) (10).